Apellis Pharmaceuticals to be Acquired by Biogen in Merger
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Apellis Pharmaceuticals ( (APLS) ) has issued an update.
On March 31, 2026, Apellis Pharmaceuticals agreed to be acquired by Biogen through a tender offer and subsequent merger, under which Apellis shareholders will receive $41.00 in cash per share plus a non-transferable contingent value right worth up to $4.00 tied to future SYFOVRE sales milestones. The tender offer, which must achieve a majority of outstanding shares and clear antitrust review, will be followed by a Delaware short-form merger without a stockholder vote, leaving Apellis as a wholly owned Biogen subsidiary if completed.
The Apellis board unanimously approved the deal as fair and recommended that shareholders tender their shares, while key insiders and Morningside Venture Investments, holding about 14% of the stock, signed a tender and support agreement committing their shares to the offer. The merger terms include a $205 million termination fee under certain break scenarios, a detailed CVR structure linked to up to $2.0 billion in annual SYFOVRE-related net sales, and an excise tax gross-up plan for executives that becomes effective only if the merger closes, underscoring strong deal protections and aligned incentives but also reflecting customary regulatory and closing risks.
The most recent analyst rating on (APLS) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Apellis Pharmaceuticals stock, see the APLS Stock Forecast page.
Spark’s Take on APLS Stock
According to Spark, TipRanks’ AI Analyst, APLS is a Neutral.
The score reflects an improving financial foundation (profitability and free cash flow turning positive, deleveraging) and a generally positive earnings call with commercial traction and pipeline progress. These positives are tempered by weak technicals (price below key moving averages with negative momentum) and a very high P/E alongside near-term net-revenue headwinds from gross-to-net/free goods dynamics.
To see Spark’s full report on APLS stock, click here.
More about Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies, including its flagship product SYFOVRE for geographic atrophy and related ophthalmic indications. The company targets markets where complement inhibition can address serious unmet medical needs, positioning it as a specialist player within the broader biotech and ophthalmology segments.
Biogen Inc. is a large U.S.-based biotechnology company with a portfolio spanning neurology and rare diseases, and it is seeking to expand its presence in ophthalmology and complement-mediated disorders through strategic acquisitions. The planned purchase of Apellis would fold Apellis into Biogen as a wholly owned subsidiary, integrating its commercial and late-stage assets into Biogen’s global platform.
Average Trading Volume: 2,832,599
Technical Sentiment Signal: Sell
Current Market Cap: $2.18B
For an in-depth examination of APLS stock, go to TipRanks’ Overview page.
